Yifan Xinfu Pharmaceutical Co Ltd (002019) - Net Assets

Latest as of March 2026: CN¥8.76 Billion CNY ≈ $1.28 Billion USD

Based on the latest financial reports, Yifan Xinfu Pharmaceutical Co Ltd (002019) has net assets worth CN¥8.76 Billion CNY (≈ $1.28 Billion USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥12.85 Billion ≈ $1.88 Billion USD) and total liabilities (CN¥4.08 Billion ≈ $597.66 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check 002019 tangible net worth ratio to evaluate the tangible quality of the company's equity base.

Key Net Assets Metrics

Metric	Value
Current Net Assets	CN¥8.76 Billion
% of Total Assets	68.2%
Annual Growth Rate	23.75%
5-Year Change	-0.73%
10-Year Change	123.33%
Growth Volatility	118.93

Yifan Xinfu Pharmaceutical Co Ltd - Net Assets Trend (2001–2025)

This chart illustrates how Yifan Xinfu Pharmaceutical Co Ltd's net assets have evolved over time, based on quarterly financial data. See 002019 cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.

Annual Net Assets for Yifan Xinfu Pharmaceutical Co Ltd (2001–2025)

The table below shows the annual net assets of Yifan Xinfu Pharmaceutical Co Ltd from 2001 to 2025. For live valuation and market cap data, see Yifan Xinfu Pharmaceutical Co Ltd (002019) total market value.

Year	Net Assets	Change
2025-12-31	CN¥8.71 Billion ≈ $1.27 Billion	+3.37%
2024-12-31	CN¥8.43 Billion ≈ $1.23 Billion	+2.08%
2023-12-31	CN¥8.25 Billion ≈ $1.21 Billion	-9.75%
2022-12-31	CN¥9.15 Billion ≈ $1.34 Billion	+4.23%
2021-12-31	CN¥8.78 Billion ≈ $1.28 Billion	+0.67%
2020-12-31	CN¥8.72 Billion ≈ $1.28 Billion	+11.45%
2019-12-31	CN¥7.82 Billion ≈ $1.14 Billion	+13.56%
2018-12-31	CN¥6.89 Billion ≈ $1.01 Billion	+1.55%
2017-12-31	CN¥6.78 Billion ≈ $992.46 Million	+73.88%
2016-12-31	CN¥3.90 Billion ≈ $570.77 Million	+35.41%
2015-12-31	CN¥2.88 Billion ≈ $421.52 Million	+13.25%
2014-12-31	CN¥2.54 Billion ≈ $372.19 Million	+560.74%
2013-12-31	CN¥384.95 Million ≈ $56.33 Million	-19.94%
2012-12-31	CN¥480.81 Million ≈ $70.36 Million	+2.41%
2011-12-31	CN¥469.52 Million ≈ $68.71 Million	-33.27%
2010-12-31	CN¥703.64 Million ≈ $102.96 Million	-22.94%
2009-12-31	CN¥913.15 Million ≈ $133.62 Million	+59.96%
2008-12-31	CN¥570.87 Million ≈ $83.54 Million	+4.07%
2007-12-31	CN¥548.55 Million ≈ $80.27 Million	+69.06%
2006-12-31	CN¥324.46 Million ≈ $47.48 Million	+1.10%
2005-12-31	CN¥320.93 Million ≈ $46.96 Million	+3.53%
2004-12-31	CN¥309.98 Million ≈ $45.36 Million	+228.68%
2003-12-31	CN¥94.31 Million ≈ $13.80 Million	+18.73%
2002-12-31	CN¥79.43 Million ≈ $11.62 Million	+51.84%
2001-12-31	CN¥52.31 Million ≈ $7.66 Million	--

Equity Component Analysis

This analysis shows how different components contribute to Yifan Xinfu Pharmaceutical Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have grown by 18350.4% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2025)

Component	Amount	Percentage
Retained Earnings	CN¥4.75 Billion	53.75%
Other Components	CN¥4.09 Billion	46.25%
Total Equity	CN¥8.83 Billion	100.00%

Yifan Xinfu Pharmaceutical Co Ltd Competitors by Market Cap

The table below lists competitors of Yifan Xinfu Pharmaceutical Co Ltd ranked by their market capitalization.

Company	Market Cap
Grupo Mateus S.A SA:GMAT3	$1.73 Billion
Polaris Bay Group Co Ltd SHG:600155	$1.73 Billion
Shanghai Jahwa United Co Ltd SHG:600315	$1.73 Billion
Zymeworks Inc. Common Stock NASDAQ:ZYME	$1.73 Billion
Hunan Oil Pump SHG:603319	$1.73 Billion
Zhejiang Hisun Pharmaceutical Co Ltd SHG:600267	$1.73 Billion
Kraken Robotics Inc V:PNG	$1.73 Billion
Guangdong Hoshion Aluminium Co Ltd SHE:002824	$1.73 Billion

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Yifan Xinfu Pharmaceutical Co Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

From 2024 to 2025, total equity changed from 8,521,867,867 to 8,834,531,175, a change of 312,663,308 (3.7%).
Net income of 402,021,184 contributed positively to equity growth.
Dividend payments of 171,577,684 reduced retained earnings.

Equity Change Factors (2024 to 2025)

Factor	Impact	Contribution
Net Income	CN¥402.02 Million	+4.55%
Dividends Paid	CN¥171.58 Million	-1.94%
Other Changes	CN¥82.22 Million	+0.93%
Total Change	CN¥-	3.67%

Book Value vs Market Value Analysis

This analysis compares Yifan Xinfu Pharmaceutical Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 1.34x
The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
The price-to-book ratio has decreased from 88.46x to 1.34x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2001-12-31	CN¥0.11	CN¥9.71	x
2002-12-31	CN¥0.17	CN¥9.71	x
2003-12-31	CN¥0.20	CN¥9.71	x
2004-12-31	CN¥0.65	CN¥9.71	x
2005-12-31	CN¥0.67	CN¥9.71	x
2006-12-31	CN¥0.74	CN¥9.71	x
2007-12-31	CN¥1.15	CN¥9.71	x
2008-12-31	CN¥1.22	CN¥9.71	x
2009-12-31	CN¥1.80	CN¥9.71	x
2010-12-31	CN¥1.26	CN¥9.71	x
2011-12-31	CN¥0.84	CN¥9.71	x
2012-12-31	CN¥0.87	CN¥9.71	x
2013-12-31	CN¥0.71	CN¥9.71	x
2014-12-31	CN¥3.72	CN¥9.71	x
2015-12-31	CN¥2.62	CN¥9.71	x
2016-12-31	CN¥3.20	CN¥9.71	x
2017-12-31	CN¥5.70	CN¥9.71	x
2018-12-31	CN¥5.48	CN¥9.71	x
2019-12-31	CN¥6.14	CN¥9.71	x
2020-12-31	CN¥6.88	CN¥9.71	x
2021-12-31	CN¥7.05	CN¥9.71	x
2022-12-31	CN¥6.91	CN¥9.71	x
2023-12-31	CN¥6.76	CN¥9.71	x
2024-12-31	CN¥7.07	CN¥9.71	x
2025-12-31	CN¥7.26	CN¥9.71	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Yifan Xinfu Pharmaceutical Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): 4.55%
The company may be facing challenges in efficiently utilizing shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: 7.83%
• Asset Turnover: 0.40x
• Equity Multiplier: 1.45x
Recent ROE (4.55%) is below the historical average (9.67%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2001	47.26%	27.07%	1.05x	1.67x	CN¥19.49 Million
2002	32.82%	19.91%	0.99x	1.66x	CN¥18.12 Million
2003	27.44%	14.64%	0.89x	2.11x	CN¥16.45 Million
2004	10.49%	13.27%	0.68x	1.16x	CN¥1.52 Million
2005	6.40%	7.60%	0.52x	1.62x	CN¥-11.53 Million
2006	2.69%	2.52%	0.58x	1.83x	CN¥-23.72 Million
2007	43.79%	31.41%	0.86x	1.61x	CN¥185.33 Million
2008	7.22%	8.59%	0.56x	1.50x	CN¥-15.85 Million
2009	3.33%	7.48%	0.36x	1.25x	CN¥-60.95 Million
2010	-28.40%	-52.00%	0.32x	1.73x	CN¥-267.11 Million
2011	-49.36%	-46.45%	0.43x	2.50x	CN¥-276.94 Million
2012	2.98%	2.22%	0.61x	2.21x	CN¥-33.76 Million
2013	30.49%	10.16%	1.72x	1.74x	CN¥79.06 Million
2014	9.35%	14.12%	0.51x	1.31x	CN¥-16.51 Million
2015	12.62%	14.81%	0.54x	1.59x	CN¥74.77 Million
2016	20.00%	20.11%	0.50x	1.98x	CN¥352.30 Million
2017	20.18%	29.84%	0.50x	1.36x	CN¥658.25 Million
2018	11.13%	15.92%	0.47x	1.48x	CN¥75.04 Million
2019	12.05%	17.42%	0.47x	1.48x	CN¥153.51 Million
2020	11.49%	17.93%	0.46x	1.39x	CN¥125.34 Million
2021	3.26%	6.31%	0.36x	1.43x	CN¥-575.18 Million
2022	2.17%	4.98%	0.31x	1.42x	CN¥-689.99 Million
2023	-6.66%	-13.55%	0.35x	1.39x	CN¥-1.38 Billion
2024	4.53%	7.48%	0.42x	1.44x	CN¥-466.22 Million
2025	4.55%	7.83%	0.40x	1.45x	CN¥-481.43 Million

Industry Comparison

This section compares Yifan Xinfu Pharmaceutical Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - General industry.

Industry Context

Industry: Drug Manufacturers - General
Average net assets among peers: $4,418,769,374
Average return on equity (ROE) among peers: 7.44%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Yifan Xinfu Pharmaceutical Co Ltd (002019)	CN¥8.76 Billion	47.26%	0.47x	$1.73 Billion
Zhejiang Int'L Group Co Ltd (000411)	$3.21 Billion	10.69%	2.51x	$732.38 Million
Zhejiang Zhenyuan Share Co Ltd (000705)	$1.98 Billion	1.15%	0.48x	$308.51 Million
Hunan Jingfeng Pharmaceutical (000908)	$-153.68 Million	0.00%	0.00x	$750.55 Million
Hubei Guangji Pharmaceutical Co Ltd (000952)	$134.18 Million	12.98%	0.83x	$302.41 Million
Guangdong Jiaying Pharmaceutical Co Ltd (002198)	$758.22 Million	2.72%	0.11x	$247.30 Million
Sichuan Kelun Pharmaceutical Co Ltd (002422)	$29.29 Billion	5.81%	0.36x	$8.36 Billion
Chongqing Lummy Pharmaceutical (300006)	$1.65 Billion	-9.38%	1.12x	$760.20 Million
Zhejiang Jolly Pharmaceutical Co Ltd (300181)	$2.77 Billion	13.80%	0.31x	$1.32 Billion
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd (300357)	$127.61 Million	29.20%	0.15x	$1.63 Billion

About Yifan Xinfu Pharmaceutical Co Ltd

SHE:002019 China Drug Manufacturers - General

Market Cap

$1.73 Billion

CN¥11.81 Billion CNY

Market Cap Rank

#6804 Global

#1513 in China

Share Price

CN¥9.71

Change (1 day)

-1.02%

52-Week Range

CN¥9.71 - CN¥16.29

All Time High

CN¥32.51